Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy

Internal Medicine

Volumn 45, Issue 7, 2006, Pages 435-441

  Suzuki, Daisuke ^a   Toyoda, Masao ^a   Yamamoto, Naoyuki ^a   Miyauchi, Masaaki ^a   Katoh, Mayuko ^a   Kimura, Moritsugu ^a   Maruyama, Mayumi ^a   Honma, Masashi ^a   Umezono, Tomoya ^a   Yagame, Mitsunori ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

Advanced glycation end products (AGE); Diabetic nephropathy; In situ hybridization; Receptor for advanced glycation end products (RAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY;

ADULT; AGED; ANALYZER; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; FEMALE; GLOMERULUS; GLOMERULUS EPITHELIUM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY BIOPSY; KIDNEY PARENCHYMA; MALE; MESANGIUM CELL; OLIGONUCLEOTIDE PROBE; PATHOGENESIS; PROTEIN EXPRESSION;

ADULT; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR MESANGIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; RECEPTORS, IMMUNOLOGIC;

EID: 33646429192     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.1557     Document Type: Article

References (36)

1. Steffes MW, Osterby R, Chavers B, Mauer SM. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38: 1077-1081, 1989.
2. Suzuki D. Measurement of the extracellular matrix in glomeruli from patients with diabetic nephropathy using an automatic image analyzer. Nippon Jinzo Gakkai shi (Jpn J Nephrol) 36: 1209-1215, 1994.
3. Suzuki D, Takano H, Toyoda M, et al. Evaluation of renal biopsy samples of patients with diabetic nephropathy. Intern Med 40: 1077-1084, 2001.
4. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Am J Med 70: 603-612, 1981.
5. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339: 69-75, 1998.
6. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318: 1315-1321, 1988.
7. Suzuki D, Yagame M, Naka R, et al. Immunohistochemical staining of renal biopsy samples in patients with diabetic nephropathy in non-insulin dependent diabetes mellitus using monoclonal antibody to advanced glycation end products. Nephrology 1: 199-205, 1995.
8. Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 10: 822-832, 1999.
9. Sell DR, Lapolla A, Odetti P, Forgarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 41: 1286-1292, 1992.
10. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thrope SR, Baynes JW, Lyons TJ. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478, 1993.
11. Beisswenger PJ, Moore LL, Brink-Johnsen T. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92: 212-217, 1993.
12. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100: 2995-3004, 1997.
13. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267: 14987-14997, 1992.
14. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992.
15. Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodeling and diabetic nephropathy. J Exp Med 174: 931-939, 1991.
16. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci USA 89: 2873-2877, 1992.
17. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712, 1993.
18. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108: 261-268, 2001.
19. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123-1137, 2003.
20. Nomoto Y, Tomino Y, Endoh M, et al. Modified open renal biopsy; Results in 934 patients. Nephron 45: 224-228, 1987.
21. Ikeda K, Higashi T, Sano H, et al. Nε-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 35: 8075-8083, 1996.
22. Suzuki D, Miyazaki M, Naka R, et al. in situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44: 1233-1238, 1995.
23. Suzuki D, Miyazaki M, Jinde K, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloprotein-1 and type IV collagen in diabetic nephropathy. Kidney Int 52: 111-119, 1997.
24. Ahmed MU, Thorpe SR, Baynes JW. Identification of Nε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261: 4889-4894, 1986.
25. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 264: 21597-21602, 1989.
26. Njoroge FG, Sayre LM, Monnier VM. Detection of glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr Res 167: 211-220, 1987.
27. el Khoury J, Thomas CA, Loike JD, Hickman SE, Cao L, Silverstein SC. Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J Biol Chem 269: 10197-10200, 1994.
28. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1: 634-646, 1995.
29. Li YM, Mitsuhashi T, Wojciechowicz D, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci 93: 11047-11052, 1996.
30. Ohgami N, Nagai R, Ikemoto M, et al. CD36 serves as a receptor for advanced glycation end products (AGE). J Diabetes Complications 16: 56-59, 2002.
31. Tanji N, Markowitz GS, Fu C, et al. The expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. J Am Soc Nephrol 11: 1656-1666, 2000.
32. Tsuji H, Iehara. N, Masegi T, et al. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem Biophys Res Commun 245: 583-588, 1998.
33. Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108: 261-268, 2001.
34. Flyvbjerg A, Denner L, Schrijvers BF, et al. Long-term renal effects of a neutralizing RAGE antibody obese type 2 diabetic mice. Diabetes 53: 166-172, 2004.
35. Wendt TM, Tanji N, Guo, J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123-1137, 2003.
36. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275: 25781-25790, 2000.